Search
for
Sort by
Research 121–150 of 777
- Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
- An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis
- Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials
- 33766 Efficacy of baricitinib in patients with various degrees of alopecia areata severity: Results from BRAVE-AA1 and BRAVE-AA2
- Topical tofacitinib for patients with lichen planopilaris and/or frontal fibrosing alopecia
- LB785 Efficacy and safety of baricitinib in adults with Alopecia Areata: Phase 3 results from a randomized controlled trial (BRAVE-AA1)
- 54022 Pooled Safety Assessments from the Multinational Phase 3 THRIVE-AA1 and THRIVE-AA2 Trials of Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata
- Alopecia universalis successfully treated with tofacitinib
- Progressive alopecia areata during TNF-α inhibition with intralesional corticosteroid failure and subsequent improvement following JAK1 inhibition
- JAK1 gain-of-function variant causes alopecia areata, atopic dermatitis, and autoimmune thyroid disease
- Successful treatment of severe diffuse alopecia areata with abrocitinib
- Ivarmacitinib stimulates hair regrowth in severe alopecia areata
- 802 Molecular effect of brepocitinib in hidradenitis suppurativa (HS)
- The development of oral hairy leukoplakia during JAK inhibitor baricitinib therapy
- Efficacy and safety of baricitinib in patients with alopecia areata: evidence to date
- 42736 Safety Assessments in the Multinational Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata
- 42752 Evaluation of Eyebrow and Eyelash Regrowth and Patient Satisfaction in the Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata
- 32237 Clinician and patient evaluation of improvement for eyebrow and eyelashes hair loss during baricitinib phase 3 trials BRAVE-AA1 and BRAVE-AA2
- Drug Armamentarium for alopecia areata
- Genes and Immune Response in Alopecia Areata: Review of the Alopecia Areata Research Summit First Day Proceedings
- Combination of baricitinib and conventional immunomodulating therapy for alopecia totalis
- A case of atopic dermatitis with alopecia universalis in a patient treated with abrocitinib
- Low-dose tofacitinib for treating patients with severe alopecia areata: an efficient and cost-saving regimen
- Treatments for Moderate-to-Severe Alopecia Areata: A Systematic Narrative Review
- INVESTIGATING THE MECHANISMS UNDERLYING THE PATHOGENESIS OF ALOPECIA AREATA
- A review of Janus kinase inhibitor use in scarring alopecia
- An urticarial drug eruption caused by tofacitinib for alopecia universalis
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
- Baricitinib for the Treatment of Alopecia Areata
- Off‐Label Use of Topical Ruxolitinib in Dermatology: A Systematic Literature Review and Current Perspectives